Infusion Reactions: Experience in Oncology Day Care Unit
Autor(a) principal: | |
---|---|
Data de Publicação: | 2021 |
Outros Autores: | , , , |
Tipo de documento: | Artigo |
Idioma: | por |
Título da fonte: | Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
Texto Completo: | https://onco.news/index.php/journal/article/view/19 |
Resumo: | The administration of antineoplastic drugs can generate immediately hypersensitivity reactions, in Oncology-Day Care Unit hospitals. The incidence and severity are difficult to predict and the signs and symptoms vary, ranging from erythematous skin reactions to severe anaphylactic reactions, with a lethal risk. Prevention is essential to reduce the prevalence and severity of these events and early recognition is a key element in resolving the condition. The objectives of the present study were: reviewing of infusion reactions in our institution, particularly, their severity, incidence, drug, subsequent reactions, type of pre- and post-medication administered. We also defined a sub-analysis to identify predictors for subsequent reactions. Observational, retrospective and single-center study, analyzing the reports of infusion reactions over 3 years. Demographic data and information regarding the infusion reaction situation were collected. Data analysis was performed using descriptive statistics, t test, Fisher’s exact test and logistic regression, using the software StataIC 15.1 (StataCorp LLC). The review of the patient’s pathological and allergic history, the monitoring compliance to premedication, therapeutic reconciliation and surveillance of vital signs are essential in the initial preinfusion assessment of antineoplastic treatments. In our study, the prevalence of infusion reactions to taxanes and platinum is in line with previous reports in the literature. Institutional reviews of adverse events are crucial to improve current practices and develop more efficient practices. |
id |
RCAP_5896b8861f66a078a2d31f38695dceeb |
---|---|
oai_identifier_str |
oai:oai.onco.news:article/19 |
network_acronym_str |
RCAP |
network_name_str |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
repository_id_str |
7160 |
spelling |
Infusion Reactions: Experience in Oncology Day Care UnitReações Infusionais: Relatos da experiência de um Hospital de Dia de OncologiaReações infusionaisFármacos antineoplásicosInfusional reactionsAntineoplasic drugsThe administration of antineoplastic drugs can generate immediately hypersensitivity reactions, in Oncology-Day Care Unit hospitals. The incidence and severity are difficult to predict and the signs and symptoms vary, ranging from erythematous skin reactions to severe anaphylactic reactions, with a lethal risk. Prevention is essential to reduce the prevalence and severity of these events and early recognition is a key element in resolving the condition. The objectives of the present study were: reviewing of infusion reactions in our institution, particularly, their severity, incidence, drug, subsequent reactions, type of pre- and post-medication administered. We also defined a sub-analysis to identify predictors for subsequent reactions. Observational, retrospective and single-center study, analyzing the reports of infusion reactions over 3 years. Demographic data and information regarding the infusion reaction situation were collected. Data analysis was performed using descriptive statistics, t test, Fisher’s exact test and logistic regression, using the software StataIC 15.1 (StataCorp LLC). The review of the patient’s pathological and allergic history, the monitoring compliance to premedication, therapeutic reconciliation and surveillance of vital signs are essential in the initial preinfusion assessment of antineoplastic treatments. In our study, the prevalence of infusion reactions to taxanes and platinum is in line with previous reports in the literature. Institutional reviews of adverse events are crucial to improve current practices and develop more efficient practices. A administração de fármacos antineoplásicos pode gerar reações de hipersensibilidade imediatas em Hospital de Dia de Oncologia. A incidência e a gravidade são difíceis de prever e os sinais e sintomas variam, podendo ir de reações cutâneas eritematosas a reações anafiláticas graves, com risco letal. A prevenção é fundamental para reduzir a prevalência e a gravidade destes eventos e o reconhecimento precoce é um elemento chave na resolução do quadro. Definimos como objetivos do presente estudo: revisão das reações infusionais na nossa instituição, particularmente, sua gravidade, incidência, fármacos envolvidos, reações subsequentes, tipo de pré e pós-medicação administradas. Definimos ainda uma sub-análise para identificação de preditores para reações subsequentes. Estudo observacional, retrospetivo e unicêntrico, de análise das notificações de reações infusionais ao longo de três anos. Foram colhidos dados demográficos e relativos à situação de reacção infusional. A análise dos dados foi realizada por meio de estatística descritiva, teste t, teste exato de Fisher e regressão logística, usando o software StataIC 15.1 (StataCorp LLC). A revisão da história patológica e alérgica do doente, a monitorização da adesão medicamentosa da pré-medicação, a reconciliação terapêutica e vigilância de sinais vitais são essenciais na avaliação inicial pré-infusional aos tratamentos antineoplásicos. No nosso estudo, a prevalência de reações infusionais aos taxanos e platinas está alinhada com relatos anteriores da literatura. Revisões institucionais sobre eventos adversos são cruciais para melhorar as práticas atuais e desenvolver protocolos de atuação mais eficientes.AEOP – Associação de Enfermagem Oncológica Portuguesa2021-06-07info:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleapplication/pdfhttps://onco.news/index.php/journal/article/view/19Onco.news; No. 42 (2021): Onco.News Journal (january-june); 38-42Onco.News; N.º 42 (2021): Revista Onco.News (janeiro-junho); 38-422183-69141646-7868reponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãoinstacron:RCAAPporhttps://onco.news/index.php/journal/article/view/19https://onco.news/index.php/journal/article/view/19/25Direitos de Autor (c) 2021 Sandra Ponte, Carla Santos Cabral, Patrícia Cavaco, Leonor Vasconcelos de Matos, Leonor Fernandesinfo:eu-repo/semantics/openAccessPonte, SandraCabral, Carla SantosCavaco, PatríciaMatos, Leonor Vasconcelos deFernandes, Leonor2024-03-16T07:55:09Zoai:oai.onco.news:article/19Portal AgregadorONGhttps://www.rcaap.pt/oai/openaireopendoar:71602024-03-20T04:01:18.835468Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãofalse |
dc.title.none.fl_str_mv |
Infusion Reactions: Experience in Oncology Day Care Unit Reações Infusionais: Relatos da experiência de um Hospital de Dia de Oncologia |
title |
Infusion Reactions: Experience in Oncology Day Care Unit |
spellingShingle |
Infusion Reactions: Experience in Oncology Day Care Unit Ponte, Sandra Reações infusionais Fármacos antineoplásicos Infusional reactions Antineoplasic drugs |
title_short |
Infusion Reactions: Experience in Oncology Day Care Unit |
title_full |
Infusion Reactions: Experience in Oncology Day Care Unit |
title_fullStr |
Infusion Reactions: Experience in Oncology Day Care Unit |
title_full_unstemmed |
Infusion Reactions: Experience in Oncology Day Care Unit |
title_sort |
Infusion Reactions: Experience in Oncology Day Care Unit |
author |
Ponte, Sandra |
author_facet |
Ponte, Sandra Cabral, Carla Santos Cavaco, Patrícia Matos, Leonor Vasconcelos de Fernandes, Leonor |
author_role |
author |
author2 |
Cabral, Carla Santos Cavaco, Patrícia Matos, Leonor Vasconcelos de Fernandes, Leonor |
author2_role |
author author author author |
dc.contributor.author.fl_str_mv |
Ponte, Sandra Cabral, Carla Santos Cavaco, Patrícia Matos, Leonor Vasconcelos de Fernandes, Leonor |
dc.subject.por.fl_str_mv |
Reações infusionais Fármacos antineoplásicos Infusional reactions Antineoplasic drugs |
topic |
Reações infusionais Fármacos antineoplásicos Infusional reactions Antineoplasic drugs |
description |
The administration of antineoplastic drugs can generate immediately hypersensitivity reactions, in Oncology-Day Care Unit hospitals. The incidence and severity are difficult to predict and the signs and symptoms vary, ranging from erythematous skin reactions to severe anaphylactic reactions, with a lethal risk. Prevention is essential to reduce the prevalence and severity of these events and early recognition is a key element in resolving the condition. The objectives of the present study were: reviewing of infusion reactions in our institution, particularly, their severity, incidence, drug, subsequent reactions, type of pre- and post-medication administered. We also defined a sub-analysis to identify predictors for subsequent reactions. Observational, retrospective and single-center study, analyzing the reports of infusion reactions over 3 years. Demographic data and information regarding the infusion reaction situation were collected. Data analysis was performed using descriptive statistics, t test, Fisher’s exact test and logistic regression, using the software StataIC 15.1 (StataCorp LLC). The review of the patient’s pathological and allergic history, the monitoring compliance to premedication, therapeutic reconciliation and surveillance of vital signs are essential in the initial preinfusion assessment of antineoplastic treatments. In our study, the prevalence of infusion reactions to taxanes and platinum is in line with previous reports in the literature. Institutional reviews of adverse events are crucial to improve current practices and develop more efficient practices. |
publishDate |
2021 |
dc.date.none.fl_str_mv |
2021-06-07 |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
https://onco.news/index.php/journal/article/view/19 |
url |
https://onco.news/index.php/journal/article/view/19 |
dc.language.iso.fl_str_mv |
por |
language |
por |
dc.relation.none.fl_str_mv |
https://onco.news/index.php/journal/article/view/19 https://onco.news/index.php/journal/article/view/19/25 |
dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
application/pdf |
dc.publisher.none.fl_str_mv |
AEOP – Associação de Enfermagem Oncológica Portuguesa |
publisher.none.fl_str_mv |
AEOP – Associação de Enfermagem Oncológica Portuguesa |
dc.source.none.fl_str_mv |
Onco.news; No. 42 (2021): Onco.News Journal (january-june); 38-42 Onco.News; N.º 42 (2021): Revista Onco.News (janeiro-junho); 38-42 2183-6914 1646-7868 reponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação instacron:RCAAP |
instname_str |
Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação |
instacron_str |
RCAAP |
institution |
RCAAP |
reponame_str |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
collection |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
repository.name.fl_str_mv |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação |
repository.mail.fl_str_mv |
|
_version_ |
1799138187137777664 |